ES2114065T3 - Metodo para el diagnostico y control de la sepsis. - Google Patents

Metodo para el diagnostico y control de la sepsis.

Info

Publication number
ES2114065T3
ES2114065T3 ES93919129T ES93919129T ES2114065T3 ES 2114065 T3 ES2114065 T3 ES 2114065T3 ES 93919129 T ES93919129 T ES 93919129T ES 93919129 T ES93919129 T ES 93919129T ES 2114065 T3 ES2114065 T3 ES 2114065T3
Authority
ES
Spain
Prior art keywords
pct
sepsis
severity
sec
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93919129T
Other languages
English (en)
Inventor
Claude Bohuon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS Diagnostica GmbH
Original Assignee
BRAHMS Diagnostica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6465882&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2114065(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BRAHMS Diagnostica GmbH filed Critical BRAHMS Diagnostica GmbH
Application granted granted Critical
Publication of ES2114065T3 publication Critical patent/ES2114065T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins

Abstract

METODO PARA DETECCION TEMPRANA, DETECCION DE LA GRAVEDAD PARA UNA VALORACION ACOMPAÑADA DE TRATAMIENTO DEL CURSO DE UNA SEPTICEMIA, ASI COMO MEDIOS PARA REALIZAR DICHO METODO. SE PRESENTA UN METODO PARA DETECCION TEMPRANA, DETECCION DE LA SEVERIDAD, ASI COMO PARA UNA VALORACION ACOMPAÑADA DE TRATAMIENTO DEL CURSO DE UNA SEPTICEMIA ASI COMO LA REALIZACION DE DICHO METODO. DE ACUERDO CON LA INVENCION, EL CONTENIDO DE LA PROCALCITONINA DE PEPTIDO Y/O DE UN PEPTIDO PARCIAL DE ESTA QUE NO LA CALCITONINA CALCINADA SE DETERMINA EN UNA MUESTRA DE UN LIQUIDO BIOLOGICO DE UN PACIENTE. A PARTIR DE LA PRESENCIA Y CANTIDAD DETERMINADAS DE DICHO PEPTIO, SE LLEGA A UNA CONCLUSION ACERCA DE LA PRESENCIA DE UNA SEPTICEMIA, SU GRAVEDAD Y/O EL EXITO DE UN TRATAMIENTO TERAPEUTICO.
ES93919129T 1992-08-19 1993-08-19 Metodo para el diagnostico y control de la sepsis. Expired - Lifetime ES2114065T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4227454A DE4227454C1 (de) 1992-08-19 1992-08-19 Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
PCT/EP1993/002245 WO1994004927A1 (en) 1992-08-19 1993-08-19 Method for diagnosing and monitoring sepsis

Publications (1)

Publication Number Publication Date
ES2114065T3 true ES2114065T3 (es) 1998-05-16

Family

ID=6465882

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93919129T Expired - Lifetime ES2114065T3 (es) 1992-08-19 1993-08-19 Metodo para el diagnostico y control de la sepsis.

Country Status (18)

Country Link
US (1) US5639617A (es)
EP (1) EP0656121B1 (es)
JP (1) JP3257796B2 (es)
CN (1) CN1050668C (es)
AT (1) ATE163767T1 (es)
AU (1) AU686114B2 (es)
BR (1) BR9306928A (es)
CA (1) CA2142599C (es)
DE (2) DE4227454C1 (es)
ES (1) ES2114065T3 (es)
HR (1) HRP931147A2 (es)
IL (1) IL106698A0 (es)
MX (1) MX9305028A (es)
NO (1) NO950594L (es)
RU (1) RU2137130C1 (es)
SI (1) SI9300433A (es)
WO (1) WO1994004927A1 (es)
ZA (1) ZA936042B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600875C1 (de) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
US8932227B2 (en) * 2000-07-28 2015-01-13 Lawrence A. Lynn System and method for CO2 and oximetry integration
US5993811A (en) * 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
WO1999027482A1 (en) * 1997-11-20 1999-06-03 Beth Israel Deaconess Medical Center Neonatal illness severity/mortality computerized determination system & method
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US7820393B2 (en) * 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
DE19903336C2 (de) * 1999-01-28 2000-12-14 Brahms Diagnostica Gmbh Gebrauchsfertige Kalibratoren für die Bestimmung von Procalcitonin
ATE356874T1 (de) 1999-12-22 2007-04-15 Dade Behring Marburg Gmbh Lösungen von humanem procalcitonin
DE50015156D1 (de) 1999-12-22 2008-06-26 Dade Behring Marburg Gmbh Gegen Procalcitonin gerichtete Antikörper, ihre Herstellung und Verwendung
US9053222B2 (en) 2002-05-17 2015-06-09 Lawrence A. Lynn Patient safety processor
US20040028651A1 (en) * 2001-03-29 2004-02-12 Karrupiah Muthumani Composition and methods of using hiv vpr
DE10119804A1 (de) * 2001-04-23 2002-10-24 Brahms Ag Entzündungsspezifische Peptide und deren Verwendungen
DE10130985B4 (de) 2001-06-27 2004-03-18 B.R.A.H.M.S Ag Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente
DE10131922A1 (de) * 2001-07-02 2003-01-30 Brahms Ag Verwendung des Calcineurin B Homologen Proteins (CHP) für die Diagnose und Therapie von Entzündungserkrankungen und Sepsis
US6939716B2 (en) * 2001-09-19 2005-09-06 Washington University Method for detecting conditions indicative of sepsis
US20050042202A1 (en) * 2001-10-05 2005-02-24 Weiner David B. Compositions for and methods of treating and preventing sirs/sepsis
ATE272214T1 (de) 2001-12-04 2004-08-15 Brahms Ag Verfahren zur diagnose von sepsis unter bestimmung von s100b
DE50103032D1 (de) * 2001-12-04 2004-09-02 Brahms Ag Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 19-9
ATE282831T1 (de) * 2001-12-04 2004-12-15 Brahms Ag Verfahren zur diagnose von sepsis unter bestimmung löslicher cytokeratinfragmente
DE50108027D1 (de) * 2001-12-04 2005-12-15 Brahms Ag Verwendung der Glycin-N-Acyl-Transferase (GNAT) für die Diagnose von Entzündungserkrankungen und Sepsis
EP1318402B1 (de) * 2001-12-04 2005-04-20 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 125
DE50103907D1 (de) * 2001-12-07 2004-11-04 Brahms Ag Verwendungen der Aldose-1-Epimerase (Mutarotase) für die Diagnose von Entzündungserkrankungen und Sepsis
US7465555B2 (en) * 2002-04-02 2008-12-16 Becton, Dickinson And Company Early detection of sepsis
EP1355158A1 (de) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Diagnose von Entzündungserkrankungen und Infektionen unter Bestimmung des Phosphoproteins LASP-1 als Inflammationsmarker
EP1355159A1 (de) 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verwendungen von Fragmenten der Carbamoylphosphat Synthetase 1 (CPS 1) für die Diagnose von Entzündungserkrankungen und Sepsis
EP1367395A1 (de) 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
EP1369693A1 (de) * 2002-06-04 2003-12-10 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Sepsisdiagnose und zur Kontrolle von Spenderblut durch Bestimmung von anti-Asialo-Gangliosid-Antikörpern
EP1369118A1 (de) * 2002-06-04 2003-12-10 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Sepsis
EP1523578A1 (en) * 2002-07-05 2005-04-20 The University of British Columbia Diagnosis of sepsis using mitochondrial nucleic acid assays
AU2003291483A1 (en) * 2002-11-12 2004-06-03 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
JP2006515670A (ja) * 2002-11-12 2006-06-01 ベクトン，ディッキンソン アンド カンパニー バイオマーカープロファイルを用いる敗血症またはｓｉｒｓの診断
MXPA05005071A (es) * 2002-11-12 2005-07-22 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
KR100540659B1 (ko) * 2003-07-02 2006-01-10 삼성전자주식회사 이미지 확대 인쇄 방법과 장치 및 컴퓨터 프로그램을저장하는 컴퓨터로 읽을 수 있는 기록 매체
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
JP2007518062A (ja) * 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
US20050170443A1 (en) * 2003-10-03 2005-08-04 Scantibodies Laboratory, Inc. Methods and use of binding components for improving assay specificity
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
EP1562046A1 (de) * 2004-02-03 2005-08-10 B.R.A.H.M.S Aktiengesellschaft Diagnose von Sepsis durch selektive Bestimmung der Konzentration der Cu/Zn Superoxiddismutase (Cu/Zn SOD) in Patientenproben
US7659087B2 (en) * 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
DE102004045705A1 (de) * 2004-09-21 2006-04-06 B.R.A.H.M.S Ag Verwendungen der Carbamoylphosphat Synthetase 1(CPS) als humoraler Biomarker für die Diagnose von Tumorerkrankungen und chronisch entzündlichen Darmerkrankungen
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20060157647A1 (en) * 2005-01-18 2006-07-20 Becton, Dickinson And Company Multidimensional liquid chromatography/spectrometry
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
JP2008538007A (ja) 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
DE102006046996A1 (de) 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
DE102006053442A1 (de) 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
DE102007009751A1 (de) * 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8097424B2 (en) * 2007-05-29 2012-01-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for predicting the outcome of a critically ill patient
EP2020603A1 (en) * 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Method for risk stratification in stable coronary artery disease
ES2403310T3 (es) * 2007-08-03 2013-05-17 B.R.A.H.M.S Gmbh Antibiótico para su utilización en una infección local
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
CA2722773C (en) 2008-05-07 2015-07-21 Lawrence A. Lynn Medical failure pattern search engine
US20100160171A1 (en) * 2008-12-22 2010-06-24 The Children's Research Institute Methods For Detection Of Sepsis
TR201806292T4 (tr) * 2009-04-28 2018-06-21 Brahms Gmbh Prokalsi̇toni̇ni̇n saptanmasi i̇çi̇n i̇mmünoloji̇k test
US20110217301A1 (en) * 2009-12-22 2011-09-08 The Children's Research Instute Methods for treating or screening for compounds for the treatment of sepsis
CN106442984B (zh) 2010-04-21 2020-03-13 米密德诊断学有限公司 区分细菌与病毒感染的标记物和决定因素以及其使用方法
KR101300601B1 (ko) * 2011-02-14 2013-08-27 충남대학교산학협력단 염증질환 및 패혈증 진단방법 및 이를 위한 키트
SI3495392T1 (sl) * 2011-05-20 2021-11-30 H. Lundbeck A/S Sestavki proti CGRP in uporaba le-teh
US20150045245A1 (en) * 2011-12-08 2015-02-12 Biocartis Nv Biomarkers and test panels useful in systemic inflammatory conditions
EP3882633A1 (en) 2012-02-09 2021-09-22 MeMed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2014009480A1 (en) 2012-07-12 2014-01-16 Universität Zürich Method for assaying sepsis and outcome in humans by detection of psp/reg
RU2519729C1 (ru) * 2012-10-19 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт общей реаниматологии имени В.А. Неговского" Российской академии медицинских наук Способ лабораторной диагностики септической энцефалопатии у новорожденных с перинатальным гипоксическим поражением цнс
US10354429B2 (en) 2012-11-14 2019-07-16 Lawrence A. Lynn Patient storm tracker and visualization processor
US9953453B2 (en) 2012-11-14 2018-04-24 Lawrence A. Lynn System for converting biologic particle density data into dynamic images
CN102928606B (zh) * 2012-11-16 2015-10-07 武汉明德生物科技股份有限公司 多抗体标记的降钙素原快速检测试剂盒
WO2014134530A1 (en) 2013-02-28 2014-09-04 Lynn Lawrence A Patient storm tracker and visualization processor
RU2549455C2 (ru) * 2013-06-18 2015-04-27 Государственное Бюджетное Учреждение Санкт-Петербургский Научно-Исследовательский Институт Скорой Помощи Им. И.И. Джанелидзе" Способ прогнозирования тяжелого сепсиса у больных с острыми отравлениями веществами наркотического действия
CN103645321A (zh) * 2013-12-03 2014-03-19 张超 一种筛查降钙素原的试纸及其制备方法
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
US10303846B2 (en) 2014-08-14 2019-05-28 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
WO2016059636A1 (en) 2014-10-14 2016-04-21 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
KR101732787B1 (ko) 2015-03-16 2017-05-08 대구한의대학교산학협력단 타깃 바이오마커에 고특이적이며 고선택적 결합이 가능한 펩타이드 프로브 및 그를 이용한 패혈증 조기진단용 바이오칩
US10005834B2 (en) * 2015-10-06 2018-06-26 Regeneron Pharmaceuticals, Inc. Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof
US11466331B2 (en) 2016-03-03 2022-10-11 Memed Diagnostics Ltd. RNA determinants for distinguishing between bacterial and viral infections
RU169868U1 (ru) * 2016-05-04 2017-04-04 Общество С Ограниченной Ответственностью Научно-Производственное Объединение "Биотест" (Ооо Нпо "Биотест") Тест-система для иммунохроматографического определения прокальцитонина в образцах цельной крови, сыворотке или плазме с целью экспресс-диагностики сепсиса
CN109804245B (zh) 2016-07-10 2022-10-25 米密德诊断学有限公司 感染的早期诊断
EP3482200B1 (en) 2016-07-10 2022-05-04 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
US11353456B2 (en) 2016-09-29 2022-06-07 Memed Diagnostics Ltd. Methods of risk assessment and disease classification for appendicitis
EP3519833A4 (en) 2016-09-29 2020-06-03 MeMed Diagnostics Ltd. PROGNOSTIC AND TREATMENT METHODS
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
EP3502706A1 (en) 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
JP7051096B2 (ja) * 2018-05-30 2022-04-11 国立大学法人山口大学 ウシプロカルシトニンを特異的に認識する抗体、その抗原結合断片、および、その使用
JP7205691B2 (ja) * 2019-01-23 2023-01-17 ウシオ電機株式会社 抗イヌプロカルシトニン抗体及びこれを用いた検査用キット

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0115459A3 (en) * 1983-01-26 1986-11-20 University Of Medicine And Dentistry Of New Jersey Hematological prediction of sepsis and other disease states
US5298605A (en) * 1986-10-08 1994-03-29 Regents Of The University Of Minnesota Antibodies to islet amyloid polypeptide (IAPP) and subunits thereof

Also Published As

Publication number Publication date
CN1050668C (zh) 2000-03-22
ZA936042B (en) 1994-02-21
BR9306928A (pt) 1996-12-03
JPH08501151A (ja) 1996-02-06
NO950594D0 (no) 1995-02-17
AU4951193A (en) 1994-03-15
DE69317289D1 (de) 1998-04-09
DE69317289T2 (de) 1998-10-08
WO1994004927A1 (en) 1994-03-03
IL106698A0 (en) 1994-11-11
MX9305028A (es) 1994-05-31
CA2142599C (en) 2004-08-03
JP3257796B2 (ja) 2002-02-18
ATE163767T1 (de) 1998-03-15
DE4227454C1 (de) 1994-02-03
NO950594L (no) 1995-04-05
EP0656121A1 (en) 1995-06-07
RU2137130C1 (ru) 1999-09-10
CN1090928A (zh) 1994-08-17
CA2142599A1 (en) 1994-03-03
AU686114B2 (en) 1998-02-05
US5639617A (en) 1997-06-17
SI9300433A (en) 1994-03-31
EP0656121B1 (en) 1998-03-04
HRP931147A2 (hr) 1995-02-28

Similar Documents

Publication Publication Date Title
ES2114065T3 (es) Metodo para el diagnostico y control de la sepsis.
Taylor et al. Suppression of nitric oxide generated by inflammatory macrophages by calcitonin gene-related peptide in aqueous humor.
DE69030956D1 (de) Inhibierung des transformierenden wachstumsfaktor zur verhinderung der anhäufung extrazellulärer matrix
BR9814615A (pt) Métodos e materiais para o tratamento e prevenção de inflamação do tecido da mucosa
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
ATE100714T1 (de) Arzneimittel (calcitoningen verwandte peptide) zur behandlung erektiler dysfunktionen.
BR0212619A (pt) Sequência de nucleotìdeo, vetor, proteìna, composição farmacêutica, dispositivo de liberação intradérmica, método para tratar um paciente que sofre de uma doença ou é suscetìvel a ela, uso de uma sequência de nucleotìdeo, e, processo para a produção de um nucleotìdeo
ES2062241T3 (es) Metodo de purificacion de la albumina serica humana.
DE69403961T3 (de) Verfahren zur bestimmung der von blutplättchen abstammenden mikrovesikel
ES2109234T3 (es) Metodo de tratamiento de la uveorretinitis autoinmune en el hombre.
AU629611B2 (en) Process for the determination, by means of free radicals, of the anti-oxidant properties of a living organism or a potentially agressive agent
ATE162721T1 (de) Neue sonde zur tumordiagnostik oder tumortherapie
BR9812101A (pt) Compostos de organossilano e uso dos mesmos
ATE142278T1 (de) Neue lederfettungsmittel und ihre verwendung
ES2180550T3 (es) Moleculas receptoras de la hormona de glycoproteina.
DK0845034T3 (da) Peptid med pronociceptive egenskaber
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
DE69214843T2 (de) Verfahren zum nachweis von beschädigungen des magenepithels
AU4593993A (en) Method and apparatus for cleaning a gas
SE9303068D0 (sv) New use
Maggi et al. Effect of thiorphan on the response of guinea-pig isolated urinary bladder to exogenous and endogenous tachykinins
Schuberth et al. 128 Starting and stopping venom immunotherapy (VIT) in children with insect allergy
FR2700323B1 (fr) Procédé de traitement biologique des eaux et dispositif mettant en Óoeuvre le procédé.
ATE321863T1 (de) Diagnostischer test für von pferdearthritisvirus verursachte krankheiten
Reisman et al. 129 Relationship of serum venom-specific IgE titers to clinical aspects of stinging insect allergy

Legal Events

Date Code Title Description
FA2A Application withdrawn

Effective date: 19960401

FG2A Definitive protection

Ref document number: 656121

Country of ref document: ES